辉瑞将如何支付三生的BD费用?

医药财经
21 May

从《辉瑞:跌落10名之外。》一文我们知道,辉瑞的账上现金流仅有14亿美元,公司在前些年买买买后负债率也较高。问题来了,辉瑞将如何支付三生的BD费用呢?辉瑞目前面临现金流紧张和高负债率的双重压力(2024年现金储备约10.4亿美元,总负债约1200亿美元),但其与三生制药达成的PD-1/VEGF双抗合作(首付款12.5亿美元+最高48亿美元里程碑付款)仍具备支付可行性。以下是具体分析:1. 短期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10